Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials

BACKGROUND: Tasquinimod is an oral quinoline-3-carboxamide derivative for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Tasquinimod has antiangiogenic, immunomodulatory, and antimetastatic properties, but it is also associated with toxicities, including skeletal pain, dig...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Ping, Liu, Hongjian, Liu, Xinyu, Zhou, Ge, Liu, Meitian, Yang, Xiaodi, Xiong, Wenjing, Wang, Qi, Ma, Juan, Ren, Zheng, He, Minfu, Zhang, Xiumin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257339/
https://www.ncbi.nlm.nih.gov/pubmed/30431595
http://dx.doi.org/10.1097/MD.0000000000013204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257339/
https://www.ncbi.nlm.nih.gov/pubmed/30431595
http://dx.doi.org/10.1097/MD.0000000000013204

Ejemplares similares